AR050174A1 - Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas - Google Patents
Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticasInfo
- Publication number
- AR050174A1 AR050174A1 ARP050102967A ARP050102967A AR050174A1 AR 050174 A1 AR050174 A1 AR 050174A1 AR P050102967 A ARP050102967 A AR P050102967A AR P050102967 A ARP050102967 A AR P050102967A AR 050174 A1 AR050174 A1 AR 050174A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- och2p
- alkynyl
- alkenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- -1 imido Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas. Reivindicacion 1: Un compuesto de formula (1), o una de sus sales, sus solvatos o profármacos aceptables desde el punto de vista farmacéutico, en los cuales; R1 se selecciona de manera independiente de H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclo, halogeno, haloalquilo, alquilsulfonamido, arilsulfonamido, -C(O)NHS(O)2-, o -S(O)2-, sustituido de manera opcional con uno o más A3; R2 es alquilo C2-10, cicloalquilo C3-7 o alquilC1-4-cicloalquiloC3-7, en el cual dicho cicloalquilo y alquil-cicloalquilo pueden estar mono-, di- o tri-sustituidos con alquilo C1-3; o en el cual dicho alquilo, cicloalquilo y alquil-cicloalquilo pueden estar mono- o di- sustituidos con sustituyentes seleccionados de hidroxi y O-alquiloC1-4; o en el cual cada uno de dichos grupos alquilo pueden estar mono-, di- o tri-sustituidos con halogeno; o en el cual uno de dichos grupos cicloalquilo que tienen 5, 6 o 7 miembros, uno o dos grupos -CH2 no están ligados directamente entre sí pueden reemplazarse por -O- de modo tal que el átomo O está unido al átomo N el cual R2 está unido a través de por lo menos dos átomos C; o R2 es fenilo, alquilC1-3-fenilo, heteroarilo o alquilC1-3-heteroaril, donde los grupos heteroarilo tienen 5 o 6 miembros que tienen de 1 a 3 heteroátomos seleccionados de N, O y S; donde dichos grupos fenilo y heteroarilo pueden estar mono-, di- o trisustituidos con sustituyentes seleccionados de halogeno -OH, alquilo C1-4, O-alquiloC1-4, S-alquiloC1-4, -NH2,-NH(alquilC1-4) y -N(alquilC1-4)2, -CONH2 y -CONH-alquiloC1-4; R3 es H o alquilo C1-6; Z es O, S, o N; Z1 es O, N, C, o S, sustituido de manera opcional con uno o más A3; Z2a es H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, donde cualquier átomo de carbono puede estar reemplazado con un heteroátomo seleccionado de O, S o N, o Z2a forma, de manera opcional, un carbociclo o heterociclo con R1, R2, Q1, o cualquier A3; Z2b es H, alquilo C1-6, alquenilo C2-8, alquinilo C2-8; Q1 es alquilo C1, alquenilo C2-8, o alquinilo C2-8; A es C o P; n es 1 o 2; A3 se selecciona de manera independiente de H, -OH, -C(O), -C(O)OH, -(CH2)m-, -C(O)O-, -NH-, ciano, alquilo, alquenilo, alquinilo, amino, imido, imino, halogeno, CF3, CH2CF3, cicloalquilo, nitro, arilo, aralquilo, alcoxi, ariloxi, heterociclo, heteroarilo, -C(A2)2, -C(A2)2-C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -CH2P(O)(A2)(OA2), - CH2P(O)(A2)(N(A2)2), -CH2P(O)(OA2)(OA2), -OCH2P(O)(OA2)(OA2), -OCH2P(O)(A2)(OA2), -OCH2P(O)(A2)(N(A2)2), -C(O)OCH2P(O)(OA2)(OA2), -C(O)OCH2P(O)(A2)(OA2), -C(O)OCH2P(O)(A2)(N(A2)2), -CH2P(O)(OA2)(N(A2)2), -OCH2P(O)(OA2)(N(A2)2), - C(O)OCH2P(O)(OA2)((N(A2)2), -CH2P(O)(N(A2)2(N(A2)2), -C(O)OCH2P(O)(N(A2)2)(N(A2)2), -OCH2P(O)(N(A2)2)(N(A2)2), -(CH2)m-heterociclo, -(CH2)mC(O)Oalquilo, O-(CH2)m-O-C(O)-Oalquilo, O-(CH2)r-O-C(O)-(CH2)m-alquilo, -(CH2)m-O-C(O)-O-alquilo, -(CH2)m-O- C(O)-O-cicloalquilo, -N(H)C(Me)C(O)O-alquilo, o alcoxi arilsulfonamida, en tanto que cada uno puede estar sustituido de manera opcional con: -R1, -P(O)(OA2)(OA2), -P(O)(OA2)(N(A2)2), -P(O)(A2)(OA2), -P(O)(A2)(N(A2)2), o P(O)(N(A2)2(N(A2)2), halogeno, alquilo, alquenilo, alquinilo, arilo, carbociclo, heterociclo, aralquilo, aril sulfonamida, aril alquilsulfonamida, ariloxi sulfonamida, ariloxi alquilsulfonamida, ariloxi arilsulfonamida, alquil sulfonamida, alquiloxi sulfonamida, alquiloxi alquilsulfonamida, -(CH2)mheterociclo, -(CH2)m-C(O)O-alquilo, O-(CH2)mOC(O)Oalquilo, O-(CH2)r-O-C(O)-(CH2)m-alquilo, -(CH2)m-O-C(O)-O-alquilo, -(CH2)m-O-C(O)-O-cicloalquilo, -N(H)C(CH3)C(O)O-alquilo, o alcoxi arilsulfonamida, sustituidos de manera opcional con R1; o A3 forma una anillo carbocíclico o heterocíclico con cualquier otro A3 o Q1; A2 se selecciona de manera independiente de H, alquilo, alquenilo, alquinilo, amino, aminoácidos, alcoxi, ariloxi, ciano, haloalquilo, cicloalquilo, arilo, heteroarilo, alquilsulfonamida, arilsulfonamida, sustituidos de manera opcional con A3; y m es de 0 a 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58863304P | 2004-07-16 | 2004-07-16 | |
| US59163504P | 2004-07-27 | 2004-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050174A1 true AR050174A1 (es) | 2006-10-04 |
Family
ID=35447172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102967A AR050174A1 (es) | 2004-07-16 | 2005-07-18 | Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7642339B2 (es) |
| EP (2) | EP1778702B1 (es) |
| JP (2) | JP5676839B2 (es) |
| KR (1) | KR20070034119A (es) |
| AP (1) | AP2461A (es) |
| AR (1) | AR050174A1 (es) |
| AT (1) | ATE516293T1 (es) |
| AU (1) | AU2005274700B2 (es) |
| BR (1) | BRPI0513426A (es) |
| CA (1) | CA2571984C (es) |
| CY (1) | CY1112453T1 (es) |
| DK (1) | DK1778702T3 (es) |
| EA (1) | EA200700336A1 (es) |
| ES (1) | ES2468441T3 (es) |
| HK (1) | HK1103089A1 (es) |
| HR (2) | HRP20070043A2 (es) |
| IL (1) | IL180288A0 (es) |
| MX (1) | MX2007000584A (es) |
| NO (1) | NO20070866L (es) |
| NZ (1) | NZ552405A (es) |
| PL (2) | PL382845A1 (es) |
| PT (1) | PT1778702E (es) |
| RS (1) | RS51974B (es) |
| TW (2) | TW200614996A (es) |
| WO (1) | WO2006020276A2 (es) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| US7273851B2 (en) * | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| US20090148407A1 (en) * | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
| DK1999129T3 (da) | 2005-10-11 | 2011-02-07 | Intermune Inc | Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2386539B1 (en) | 2005-12-23 | 2016-07-20 | Zealand Pharma A/S | 4-Aminoproline derivatives useful as lysine mimetics |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| AP2008004721A0 (en) * | 2006-07-07 | 2008-12-31 | Gilead Sciences Inc | Antiviral phosphinate compounds |
| US20090227491A1 (en) * | 2006-07-07 | 2009-09-10 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| AU2013200563C1 (en) * | 2006-07-07 | 2015-05-14 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| WO2008008776A2 (en) * | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2008008502A1 (en) | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| US20090035271A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| CA2656816A1 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| CN101541826A (zh) * | 2006-09-13 | 2009-09-23 | 诺瓦提斯公司 | 大环hcv抑制剂及其用途 |
| US8377873B2 (en) * | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008079266A2 (en) | 2006-12-21 | 2008-07-03 | Wyeth | Synthesis of pyrrolidine compounds |
| US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
| CA2677015C (en) * | 2007-02-08 | 2015-05-26 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phenylcarbamates |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| WO2008134397A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| AR066528A1 (es) | 2007-05-10 | 2009-08-26 | Array Biopharma Inc | Peptidos inhibidores de la replicacion del virus de la hepatitis c |
| AU2014200403B2 (en) * | 2007-06-29 | 2016-05-19 | Gilead Sciences, Inc. | Antiviral compounds |
| AR067180A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| MX2009013830A (es) | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
| US8178491B2 (en) * | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| CN102026544A (zh) | 2007-11-14 | 2011-04-20 | 益安药业 | 大环四唑基丙型肝炎病毒丝氨酸蛋白酶抑制剂 |
| US8263549B2 (en) * | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
| US8030307B2 (en) * | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| MX2010006738A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| CN101951770B (zh) | 2007-12-21 | 2014-12-31 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| MX2010008523A (es) | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
| US8372802B2 (en) | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
| US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT2364309E (pt) | 2008-12-10 | 2015-01-14 | Achillion Pharmaceuticals Inc | Novos péptidos 4-amino-4-oxobutanoil como inibidores de replicação viral |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| CN109020961A (zh) | 2009-05-13 | 2018-12-18 | 吉利德制药有限责任公司 | 抗病毒化合物 |
| KR20100127948A (ko) * | 2009-05-27 | 2010-12-07 | 한국전자통신연구원 | Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용 |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US7924650B2 (en) * | 2009-06-30 | 2011-04-12 | Oracle America, Inc. | Dynamically controlled voltage regulator for a memory |
| CA2769652A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US8927484B2 (en) * | 2009-12-03 | 2015-01-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| JP5905020B2 (ja) | 2010-11-17 | 2016-04-20 | ギリアド ファーマセット エルエルシー | 抗ウイルス化合物 |
| JP2014506255A (ja) | 2010-12-30 | 2014-03-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | フェナントリジン大環状ｃ型肝炎セリンプロテアーゼ阻害剤 |
| WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP3199537B1 (en) | 2011-05-19 | 2018-10-17 | Gilead Sciences, Inc. | Processes and intermediates for preparing anti-hiv agents |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT3431477T (pt) | 2011-11-16 | 2020-12-15 | Gilead Pharmasset Llc | Imidazolilimidazolos condensados como compostos antivirais |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| CN104822682A (zh) | 2012-10-08 | 2015-08-05 | 艾伯维公司 | 用于制备hcv蛋白酶抑制剂的化合物 |
| BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN105073758B (zh) | 2013-03-15 | 2017-08-11 | 吉利德科学公司 | 丙型肝炎病毒抑制剂 |
| US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
| US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| KR20160005686A (ko) | 2013-03-15 | 2016-01-15 | 아칠리온 파르마세우티칼스 인코포레이티드 | 소바프레비르 다형체들 및 이의 제조 방법 |
| US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CA2972259A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| ES2870106T3 (es) | 2017-05-05 | 2021-10-26 | Zealand Pharma As | Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético |
| ES2969496T3 (es) | 2017-08-01 | 2024-05-20 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN110892989B (zh) * | 2019-06-27 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解便秘功能的副干酪乳杆菌et-22 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| AU651835B2 (en) | 1990-06-13 | 1994-08-04 | Arnold Glazier | Phosphorous prodrugs |
| ATE167679T1 (de) * | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| UA79749C2 (en) * | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| US6018049A (en) * | 1996-12-26 | 2000-01-25 | Shionogi & Co., Ltd. | Process for the preparation of carbamoylated imidazole derivatives |
| IL134232A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| JP3889708B2 (ja) | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎トリペプチド阻害剤 |
| KR100567706B1 (ko) * | 2001-01-31 | 2006-04-05 | 워너-램버트 캄파니 엘엘씨 | 알코올의 카르바모일화 방법 |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| ES2361011T3 (es) * | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| PL211889B1 (pl) * | 2002-05-20 | 2012-07-31 | Bristol Myers Squibb Co | Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie |
-
2005
- 2005-07-18 EP EP05791144A patent/EP1778702B1/en active Active
- 2005-07-18 WO PCT/US2005/025503 patent/WO2006020276A2/en active Application Filing
- 2005-07-18 JP JP2007521717A patent/JP5676839B2/ja not_active Expired - Fee Related
- 2005-07-18 AU AU2005274700A patent/AU2005274700B2/en not_active Ceased
- 2005-07-18 AP AP2007003895A patent/AP2461A/xx active
- 2005-07-18 NZ NZ552405A patent/NZ552405A/en not_active IP Right Cessation
- 2005-07-18 AT AT05791144T patent/ATE516293T1/de active
- 2005-07-18 EP EP10178084.9A patent/EP2316839B1/en active Active
- 2005-07-18 EA EA200700336A patent/EA200700336A1/ru unknown
- 2005-07-18 MX MX2007000584A patent/MX2007000584A/es active IP Right Grant
- 2005-07-18 PL PL382845A patent/PL382845A1/pl not_active Application Discontinuation
- 2005-07-18 AR ARP050102967A patent/AR050174A1/es not_active Application Discontinuation
- 2005-07-18 DK DK05791144.8T patent/DK1778702T3/da active
- 2005-07-18 US US11/184,429 patent/US7642339B2/en active Active
- 2005-07-18 RS RS20110436A patent/RS51974B/en unknown
- 2005-07-18 KR KR1020077003918A patent/KR20070034119A/ko active IP Right Grant
- 2005-07-18 US US11/632,180 patent/US20080311077A1/en not_active Abandoned
- 2005-07-18 PT PT05791144T patent/PT1778702E/pt unknown
- 2005-07-18 PL PL05791144T patent/PL1778702T3/pl unknown
- 2005-07-18 BR BRPI0513426-9A patent/BRPI0513426A/pt not_active IP Right Cessation
- 2005-07-18 CA CA2571984A patent/CA2571984C/en not_active Expired - Fee Related
- 2005-07-18 ES ES10178084.9T patent/ES2468441T3/es active Active
- 2005-07-19 TW TW094124376A patent/TW200614996A/zh unknown
- 2005-07-19 TW TW101104372A patent/TW201228665A/zh unknown
-
2006
- 2006-12-25 IL IL180288A patent/IL180288A0/en unknown
-
2007
- 2007-02-09 HR HR20070043A patent/HRP20070043A2/xx not_active Application Discontinuation
- 2007-02-15 NO NO20070866A patent/NO20070866L/no not_active Application Discontinuation
- 2007-10-26 HK HK07111565.5A patent/HK1103089A1/xx unknown
-
2011
- 2011-10-10 CY CY20111100970T patent/CY1112453T1/el unknown
- 2011-10-11 HR HR20110732T patent/HRP20110732T1/hr unknown
-
2012
- 2012-02-06 JP JP2012023052A patent/JP5767984B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050174A1 (es) | Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas | |
| AR054838A1 (es) | Compuestos inhibidores del virus de la hepatitis c | |
| AR061840A1 (es) | Compuestos fosfinatos antivirales | |
| AR054837A1 (es) | Compuestos inhibidores del virus de la hepatitis c | |
| CO6251241A2 (es) | Compuestos de prolina modificados con actividad anti-vhc | |
| AR060990A1 (es) | Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes | |
| AR053153A1 (es) | Derivados de pirazina -2- carboxamida como antagonistas de mglur5 | |
| AR057891A1 (es) | Compuestos de oxazol y composicion farmaceutica | |
| AR051195A1 (es) | Piridinas como inhibidores de plk | |
| AR054232A1 (es) | Derivados de piridina -2- carboxamida como antagonistas de mglur5 | |
| AR059512A1 (es) | Derivados de piridina -2- carboxamida | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20090042A1 (es) | Analogos de ciclopamina | |
| AR060405A1 (es) | Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR039112A1 (es) | Inhibidores de quinasas | |
| AR045938A1 (es) | Peptidos macrociclicos activos contra el virus de la hepatitis c | |
| AR081831A1 (es) | Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc) | |
| AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
| AR038863A1 (es) | Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero | |
| AR037882A1 (es) | Cis-imidazolinas | |
| PE20231066A1 (es) | Agonistas heterociclicos de glp-1 | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |